SOUTH
SAN FRANCISCO, Calif., Nov. 1, 2023
/PRNewswire/ -- IDEAYA Biosciences, Inc. (NASDAQ: IDYA), a
precision medicine oncology company committed to the discovery and
development of targeted therapeutics, announced its participation
in the Jefferies London Healthcare Conference and its plans to host
an Investor R&D Day in December
2023.
Jefferies London Healthcare Conference
Tuesday, November 14th,
2023 at 8:00 AM GMT | 3:00 AM ET
- Fireside chat with Yujiro S. Hata, Chief Executive
Officer, hosted by Maury Raycroft,
Ph.D. Equity Research Analyst, Biotechnology
IDEAYA Biosciences Investor R&D Day
Monday, December 4th, 2023
at 8:00 AM ET
- The IDEAYA Investor R&D Day will include participation from
GSK and a key opinion leader that will showcase scientific insights
and clinical development opportunities across IDEAYA's synthetic
lethality pipeline, including IDE397 (MAT2A) in Phase 2, IDE161
(PARG) in Phase 1, and the GSK partnered programs. In addition,
IDEAYA will highlight its next generation initiatives in
MTAP-deletion, including a wholly-owned program where a development
candidate nomination is targeted in 2024, further advancing
IDEAYA's multi-pronged strategy.
- Pre-registration will be available through IDEAYA's investor
relations events page at https://ir.ideayabio.com/events
A live audio webcast of conference events, as permitted by
conference host, will be available at the "Investors/News and
Events/Investor Calendar" section of the IDEAYA website at
https://ir.ideayabio.com/events. A replay of available webcasts
will be accessible for 30 days following the live event.
__________________
About IDEAYA Biosciences
IDEAYA is a precision medicine oncology company committed to the
discovery and development of targeted therapeutics for patient
populations selected using molecular diagnostics. IDEAYA's
approach integrates capabilities in identifying and validating
translational biomarkers with drug discovery to select patient
populations most likely to benefit from its targeted
therapies. IDEAYA is applying its early research and drug
discovery capabilities to synthetic lethality – which represents an
emerging class of precision medicine targets.
__________________
Forward-Looking Statements
This press release contains forward-looking statements,
including, but not limited to, statements related to participation
in, presentation at, and/or content of certain investor relations
events. IDEAYA undertakes no obligation to update or revise any
forward-looking statements. For a further description of the risks
and uncertainties that could cause actual results to differ from
those expressed in these forward-looking statements, as well as
risks relating to the business of IDEAYA in general, see IDEAYA's
Quarterly Report on Form 10-Q filed on August 10, 2023 and any current and periodic
reports filed with the U.S. Securities and Exchange Commission.
___________________
Investor and Media Contact
IDEAYA Biosciences
Andres Ruiz Briseno
Senior Vice President, Head of Finance and Investor Relations
investor@ideayabio.com
View original content to download
multimedia:https://www.prnewswire.com/news-releases/ideaya-biosciences-announces-plans-for-investor-rd-day-and-participation-in-jefferies-london-healthcare-conference-301973606.html
SOURCE IDEAYA Biosciences, Inc.